Neoepitope-Loaded Dendritic Cells for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell vaccines face challenges in effectively activating anticancer immune cells due to severe chronic inflammatory phenomena and the presence of immunosuppressive cytokines, immunosuppressive T cells, and dendritic cells within the cancer microenvironment, limiting their clinical efficacy in gastric cancer treatment.
Innovation Solution
Development of a cancer-specific tumor antigen neoepitope derived from Epstein-Barr virus (EBV)-positive cancer cells, specifically Epstein-Barr virus latent membrane protein 2 (LMP2a) and Epstein-Barr nuclear antigen 1 (EBNA-1), which are recognized by T cell receptors, and their use in loading antigen-presenting cells to activate T cells for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell vaccines are used for cancer treatment, then antigen presentation to T cells is improved, but severe chronic inflammatory phenomena and immunosuppression occur in the cancer microenvironment
Solution Approach 1:
The invention segments the complex dendritic cell vaccine approach into distinct components: specific neoepitope identification (LMP2a and EBNA-1 for EBV-positive gastric cancer), targeted antigen presentation methods, and controlled delivery systems. This segmentation allows optimization of each component to reduce inflammatory and immunosuppressive effects while maintaining antigen presentation efficacy.
Solution Approach 2:
The patent introduces specially designed antigen-presenting cells as intermediaries that bridge the gap between the cancer neoepitopes and the patient's T cells. These engineered APCs are loaded with specific cancer antigens and designed to present them in a controlled manner that avoids the harmful inflammatory and immunosuppressive responses associated with conventional dendritic cell vaccines.
2Reliability
If conventional dendritic cell vaccines are administered, then T cell activation is attempted, but cancer cells secrete immunosuppressive substances that prevent appropriate immune response
Solution Approach 1:
The invention performs preliminary action by pre-loading antigen-presenting cells with specific cancer neoepitopes (LMP2a and EBNA-1) before administration. This preliminary preparation ensures that the APCs are equipped with the exact antigens needed to activate T cells effectively, overcoming the immunosuppressive environment created by cancer cells. The patent also pre-identifies patient-specific neoepitopes through genomic sequencing, allowing customized vaccine preparation that anticipates and overcomes cancer cell evasion mechanisms.
Solution Approach 2:
The patent applies parameter changes by modifying the antigen presentation parameters - using specifically identified neoepitopes with high binding affinity to HLA molecules, optimizing the ratio of antigen to APCs, and controlling the maturation state of dendritic cells. These parameter optimizations enable effective T cell activation even in the presence of cancer cell-secreted immunosuppressive substances.
3Object-affected harmful factors
If patient-derived T cells are used for therapy, then immune response induction is reduced, but production time and cost increase
Solution Approach 1:
The patent applies partial action by using a simplified approach that does not require full T cell isolation, expansion, and reinfusion protocols. Instead, the invention uses engineered antigen-presenting cells that can activate endogenous T cells directly in the patient's body, achieving therapeutic effects with less extensive T cell manipulation and shorter production times.
4Reliability
If ex vivo dendritic cell culture is performed, then antigen presentation capability is improved, but culture time and complexity increase
Solution Approach 1:
The invention segments the complex ex vivo dendritic cell culture process into simplified, standardized steps with defined protocols for each stage (isolation, differentiation, antigen loading, maturation). This segmentation reduces overall process complexity while maintaining antigen presentation capability. The patent also segments the antigen loading process into separate, optimized steps for different antigen types and delivery methods.
Solution Approach 2:
The patent optimizes culture parameters including cytokine concentrations, incubation times, temperature profiles, and pH levels to achieve effective dendritic cell differentiation and antigen loading with reduced culture time. These parameter optimizations maintain high antigen presentation capability while simplifying the overall culture process and reducing operational complexity.
Data Source
AI summary
The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 184, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.